DOCSLIB.ORG

Lab Info | 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lab Info | 2019 LAB INFO | 2019 LABORATORY INFORMATION GUIDE SEPTEMBER 2019 aruplab.com Information in this brochure is current as of September 2019. All content is subject to change. Please contact ARUP Client Services at 800-522-2787 with any questions or concerns. ARUP LABORATORIES As a nonprofit, academic institution of the University of Utah and its Department We believe in of Pathology, ARUP believes in collaborating, sharing knowledge, and contributing to laboratory science in ways that benefit our clients and their patients. collaborating, Our test menu is one of the broadest in the industry, encompassing more sharing than 3,000 tests, including highly specialized and esoteric assays. We offer comprehensive testing in the areas of genetics, molecular oncology, pediatrics, knowledge, and and pain management, among others. contributing ARUP’s clients include many of the nation’s university teaching hospitals to laboratory and children’s hospitals, as well as multihospital groups, major commercial laboratories, and group purchasing organizations. We do not compete with our science in ways clients for physician office business, choosing instead to support clients’ existing test menus by offering highly complex assays and accompanying consultative that provide support so clients can provide exceptional patient care in their local communities. the best value Offering analytics, consulting, and decision support services, ARUP provides clients with the utilization management tools necessary to prosper in this time of for the patient. value-based care. Our UM+ program helps clients control utilization, reduce costs, Together, and improve patient care. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for ARUP and ® Clinical and Experimental Pathology . its clients will ARUP’s reputation for quality is supported by our ability to meet or exceed the requirements of multiple regulatory and accrediting agencies and organizations. improve patient ARUP participates in the CAP laboratory accreditation program and has CLIA care today and certification through the Centers of Medicare and Medicaid Services. In December 2016, ARUP earned accreditation to the ISO 15189:2012 standard under CAP. in the future. patients. answers. results.® A laboratory test is more than a number; it is a person, an answer, a diagnosis.® . TABLE OF CONTENTS CHEMISTRY DIVISION ..................... 1–7 Molecular Genetics. .24 Analytic Biochemistry. 1 Molecular Oncology . 25 Automated Core . 1 Supplemental Newborn Screening. 25 Calculi and Manual Chemistry . 2 Clinical Toxicology I. 2 ARUP INSTITUTE FOR CLINICAL & Clinical Toxicology II . .3 EXPERIMENTAL PATHOLOGY® ........... 26–27 Clinical Toxicology III. 3 Research and Development. 26 Automated Endocrinology . 4 Specialized Technologies and Manufacturing . 26 Endocrinology/Electrophoresis. 4 Technology Transfer. 27 Hemostasis/Thrombosis . 5 Manual Endocrinology I . 5 TECHNICAL SUPPORT .................. 28–29 Mass Spectrometry I and II. .6 Automated Specimen Management (ASM). 28 Special Chemistry. .6 Infectious Disease Processing . .28 Trace and Toxic Elements . 7 Integrated Oncology and Genetics Services . .29 Description . 29 IMMUNOLOGY DIVISION ................. 8–11 Specimen Processing . 29 Autoimmune Immunology I . 8 Autoimmune Immunology II. 8 TRANFUSION MEDICINE .................... 30 Cellular and Innate Immunology . 9 Blood Services. .30 Immunologic Flow Cytometry. 9 Immunohematology Reference Laboratory (IRL) 30 Immunology Core . 10 Transfusion Services. 30 Microbial Immunology I. .10 Microbial Immunology II. .10 UNIVERSITY OF UTAH HEALTH ............... 31 Protein Immunology. 11 University Hospitals and Clinics, Clinical Lab. 31 Serologic Hepatitis/Retrovirus . 11 CLIENT COMMITMENT ...................... 31 INFECTIOUS DISEASE. 12–17 Client Commitment Statement . 31 Bacteriology. .12 Infectious Disease Antigen Testing . .12 Microbial Amplified Detection . 13 Molecular Hepatitis/Retrovirus . 13 Molecular Infectious Disease . 14 Mycology AFB . .14 Parasitology and Fecal Testing . 15 Sequencing Infectious Disease. 15 Special Microbiology. 16 Virology. .16 INTEGRATED ONCOLOGY AND GENETICS 17–25 Anatomic Pathology. 17 Biochemical Genetics . 17 Cytogenetics and Genomic Microarray. 18 Cytopathology . .18 Fragment Analysis. 19 Genetics Sequencing . .20 Genomics . .21 Hematologic Flow Cytometry . 22 Special Hematology . 22 Histology. 23 Immunohistochemistry . .23 CHEMISTRY DIVISION ANALYTIC BIOCHEMISTRY Description This technical section primarily uses high-performance liquid chromatography (HPLC) combined with various detection systems, including mass spectrometry (MS), electrochemical, UV, and fluorometric. Testing is focused on nutritional assessment, pophyrins, and biogenic amines. Testing Areas • 5-HIAA • Porphyrins • Vitamin B6 • Catecholamines • Serotonin • Vitamin C • Coenzyme Q10 • Sulfate, Supersaturation • Vitamin E • Fractionated Carotenes • Vitamin A • Vitamin K • HVA • Vitamin B1 • VMA • Metanephrines • Vitamin B2 Methodologies Spectrophotometry, chromatography, mass spectrometry, and fluorometry Instrumentation HPLC, MS, electrochemical detector (ECD), UV detector, spectrophotometer, and fluorometer AUTOMATED CORE Description This technical section primarily uses high-throughput automated analyzers. Test selection is focused on assays requiring no manual manipulation. The lab currently performs more than 20 percent of all testing performed at the central facility. Testing Areas 200 different assays performed on various types of samples (serum, urine, CSF, and amniotic fluid), including: • Drugs of abuse screening by immunoassay • Endocrine testing: T3, T4, TSH, testosterone, SHBG, ferritin, folate, B12, insulin, PTHI, and thyroglobulin • General chemistries: electrolytes, enzymes, BUN, creatinine, and glucose • Maternal serum screen: alpha fetoprotein, hCG, estriol, and inhibin A • Tumor markers: CA 125, CA 15-3, CA 19-9, CEA, PSA, AFP TM, and hCG Methodologies Ion-selective electrode/enzymatic, chemiluminescent immunoassay, electrochemiluminescent immunoassay, immunoturbidimetric, spectrophotometry Instrumentation Ortho Clinical Diagnostics, Beckman Coulter, and Roche Diagnostics analyzers 1 CHEMISTRY DIVISION CALCULI AND MANUAL CHEMISTRY Description This technical section primarily uses Fourier-transform infrared spectroscopy (FT-IR) for calculi analysis. Testing specializes in calculi (stone) analysis, calculi photomicrographs, calculi risk assessments, visocometry assessment, and nutritional status. Testing Areas • Calculi • Calculi risk assessments • Calculi photomicrographs • Carotenes • Sulfate • Viscosity • Supersaturation risk calculations Methodologies FT-IR, FT-IR microscopy, polarizing microscopy, photomicroscopy, spectrophotometry, viscometry Instrumentation FT-IR, FT-IR microscope, stereomicroscope, spectrophotometer, cone-plate viscometer CLINICAL TOXICOLOGY I Description This laboratory analyzes urine, serum, and plasma to detect drugs of abuse for treatment-rehabilitation centers, pain management clinics, and hospitals. No chain of custody, employment, or forensic sample testing is performed. Testing Areas Qualitative and quantitative testing for commonly abused prescription and illicit drugs. Screens with reflex to confirmation and confirmation-only testing are available. Drug testing is designed to support clinical applications, including: • Compliance testing for pain management clinics • Qualification for patients for surgery or other interventions • Verification of drug abstinence • Confirmation of previously obtained screening results Methodologies GC-MS, LC-MS/MS Instrumentation Agilent Technologies, AB Sciex, and Waters mass spectrometry systems 2 CHEMISTRY DIVISION CLINICAL TOXICOLOGY II Description This laboratory performs approximately 40 quantitative assays for more than 100 drugs. Comprehensive screening is also performed to detect the presence of up to 250 drugs, including over-the-counter and prescription drugs, as well as some drugs of abuse. Testing Areas • Anticonvulsant drugs • Antidepressant drugs • Antifungal drugs • Antipsychotic drugs • Cardiac drugs • Immunosuppressant drugs Methodologies Spectrophotometric assays, immunoassay (ELISA), GC-MS, LC-MS/MS Instrumentation Agilent Technologies, AB Sciex, and Waters mass spectrometry systems CLINICAL TOXICOLOGY III Description This laboratory analyzes serum, plasma, meconium, and umbilical cord tissue to detect drugs of abuse for hospitals, pain management clinics, and treatment-rehabilitation centers. No chain of custody, employment, or forensic sample testing is performed. Testing Areas Qualitative and quantitative testing for commonly abused prescription and illicit drugs. Screens with reflex to confirmation and confirmation-only testing are available. Drug testing is designed to support clinical applications, including: • Identification of in utero drug exposure • Compliance testing for pain management clinics • Qualification for patients for surgery or other interventions • Verification of drug abstinence • Confirmation of previously obtained screening results Methodologies ELISA, GC-MS, LC-MS/MS Instrumentation Agilent Technologies, AB Sciex, and Waters mass spectrometry systems 3 CHEMISTRY DIVISION AUTOMATED ENDOCRINOLOGY Description This technical section primarily uses high-throughput automated analyzers. Test selection is focused on assays not fitting into the Automated Core Lab that may require limited manual manipulation prior
Load more

Recommended publications
  • ARUP Laboratories & the University of Utah Department Of
    & ARUP LABORATORIES & THE UNIVERSITY OF UTAH DEparTMENT OF paTHOLOGY March 2014 Message from the President & CEO ARUP Leadership About ARUP what’s Culture of Innovation inside Automation Initiative Unique Relationships ARUP Medical Directors & Consultants ARUP History & Timeline CONSISTENCY, SUCCESSS, EXPERIENCE ARUP LEADERSHIP ARUP BOarD OF DIRECTORS ARUP EXECUTIVE TEAM Peter E. JENSEN, MD Peter E. JENSEN, MD Chairman Chair, Department of Pathology, University of Utah Chair, Department of Pathology, University of Utah EDWard R. ASHWood, MD EDWard R. ASHWood, MD President and CEO President and CEO Julie AltWieS, BS H. ROGer BOYer Vice President, Director of Sales The Boyer Company NaNCY ANdeS, MBA, MT(ASCP) ARNold B. Combe Senior Vice President, Marketing University of Utah LESlie T. HamiltoN, MT(ASCP)SM CLARK D. IVORY Senior Vice President, Technical Operations University of Utah JerrY W. HUSSONG, MD, MS SuSAN D’ANjou JohNSON Vice President, Chief Medical Officer/Director of Futura Industries Laboratories Carl R. KjeldSberG, MD BriaN R. JackSON, MD, MS University of Utah Vice President, Chief Medical Informatics Officer LeeANNE B. LINdermaN David P. JackSON, MBA Zions Bank Senior Vice President, Strategic Services JameS L. MacFarlaNE JohN R. PENroSE, BS IC Group Senior Vice President, Chief Information Officer JohN K. MorriS Sherrie L. PerkiNS, MD, PHD Non-voting Member Senior Vice President, Research and Development, Office of General Counsel, University of Utah Co-Executive Director, ARUP Institute for Clinical and Experimental Pathology ANdreW A. Theurer, CPA Board Secretary KhoSroW ShotorbaNI, MBA, MT(ASCP) Senior Vice President, Business Innovations SHERRIE L. PERKINS, MD, PHD Invited Guest ANdreW A. Theurer, CPA, BA Senior Vice President, Chief Financial Officer CONSISTENCY, SUccESS, experience EXECUTIVE MANAGEMENT TEAM The executive management team’s maturity and devotion to patient care and leadership, from both the medical and business sides of health care, sustains ARUP as a valuable asset to its clients and the lab industry.
    [Show full text]
  • Ige – the Main Player of Food Allergy
    DDMOD-431; No of Pages 8 Vol. xxx, No. xx 2016 Drug Discovery Today: Disease Models Editors-in-Chief Jan Tornell – AstraZeneca, Sweden DRUG DISCOVERY Andrew McCulloch – University of California, SanDiego, USA TODAY DISEASE MODELS IgE – the main player of food allergy 1 2,3 2 Henrike C.H. Broekman , Thomas Eiwegger , Julia Upton , 4, Katrine L. Bøgh * 1 Department of Dermatology/Allergology, University Medical Centre Utrecht (UMCU), Utrecht, The Netherlands 2 Division of Immunology and Allergy, Food Allergy and Anaphylaxis Program, The Department of Paediatrics, Hospital for Sick Children, Toronto, Canada 3 Research Institute, Physiology and Experimental Medicine, The University of Toronto, Toronto, Canada 4 National Food Institute, Technical University of Denmark, Søborg, Denmark Food allergy is a growing problem worldwide, presently Section editor: affecting 2–4% of adults and 5–8% of young children. IgE Michelle Epstein – Medical University of Vienna, is a key player in food allergy. Consequently huge Department of Dermatology, DIAID, Experimental Allergy, Waehringer Guertel 18-20, Room 4P9.02, A1090, efforts have been made to develop tests to detect Vienna, Austria. either the presence of IgE molecules, their allergen binding sites or their functionality, in order to provide allergen ingestion [1], and involve one or more of the follow- information regarding the patient’s food allergy. The ing systems; the skin (pruritus, urticaria, or angioedema), the ultimate goal is to develop tools that are capable of gastro-intestinal tract (diarrhea, vomiting, contractions, in- creased bowel movement), the respiratory tract (asthma at- discriminating between asymptomatic sensitization tack, hoarseness, stridor/laryngeal angioedema) or the and a clinically relevant food allergy, and between cardiovascular system (dizziness, drop in blood pressure, loss different allergic phenotypes in an accurate and trust- of consciousness) [2,3].
    [Show full text]
  • Role of Serologic Testing in Rheumatic Diseases
    Role of Serologic Testing in Rheumatic Diseases Debendra Pattanaik MD FACP Associate professor of Medicine UTHSC, Memphis TN Disclosure None Objectives Discuss commonly available serologic testing useful in daily clinical practice Recognize the serologic associations of rheumatic diseases Recognize their diagnostic utilities and limitations Diagnostic Accuracy for Lupus and other autoimmune diseases in the community setting 476 patients were evaluated at Autoimmunity Center of University of Florida, Gainesville for 13 months which were by from primary care physicians SLE was over diagnosed on many patients on the basis of + ANA 39 patients are taking prednisone 60 mg/day who have no autoimmune disease but only have + ANA Inappropriate diagnosis leads to inappropriate therapy, emotional and financial consequences The authors suggested continuing education in screening for autoimmune disease and identify patients who may benefit from early referral. Arch Intern Med. 2004;164:2435-2441 Antinuclear Antibody (ANA) Testing for Connective Tissue Disease British Columbia Population: 4.631 million. More than 94,000 ANA tests were performed in B.C. in fiscal year 2011/12 at a cost of $2.24 million annually. Incidence and Estimated New Cases in B.C. for Selected CTDs Connective Tissue Disease Disease incidence per million population Estimated new BC cases/year * Systemic lupus erythematosus 56 259 Scleroderma 19 88 Dermatomyositis & polymyositis < 10 < 46 Eighteen percent of first-time tested outpatients underwent unnecessary repeat testing in 2010/2011. In 57.2% of the repeat testing, both the initial and the repeat ANA tests were ordered by a GP. In 24.8% the initial test was ordered by a GP and the repeat test was ordered by a specialist, and in 10.2% both the initial and the repeat test were ordered by the same specialist.
    [Show full text]
  • The University of Utah a Component Unit of the State of Utah 2017
    ANNUAL FINANCIAL REPORT THE UNIVERSITY OF UTAH A COMPONENT UNIT OF THE STATE OF UTAH 2017 TABLE OF CONTENTS Message from the President 2 - 3 Independent State Auditor’s Report 4 - 5 Management’s Discussion and Analysis 6 - 14 Financial Statements 15 - 20 Statement of Net Position 16 - 17 Statement of Revenues, Expenses, and Changes in Net Position 18 Statement of Cash Flows 19 - 20 Notes to Financial Statements 21 - 46 Required Supplementary Information 47 - 49 Governing Boards and Officers 50 Message from the President David W. Pershing ne hundred years ago, John A. Widtsoe, president of the University of Utah, declared that he hoped to see “this institution enter into the very life of our state; to help solve its problems, to Opoint its way, to help bear its burdens as well as to share in its prosperity…” It was understood then, as it is today, the responsibility of the flagship institution extends beyond its classrooms and laboratories. The University of Utah has become a world-class research and teaching institution, an engine of economic prosperity, and a provider of nationally recognized medical care. The U plays an integral role within the state, as was hoped, but the university’s positive influence now has a global impact. The success of the University of Utah is reliant on the responsible stewardship of intellectual, physical, and financial resources. We gratefully acknowledge critical contributions made by the residents and elected leaders of this state, as well as the Utah State Board of Regents and our Board of Trustees. The U excels because of their support.
    [Show full text]
  • Importance of Ag-Ab Reactions
    Ag-Ab reactions Tests for Ag-Ab reactions EISA SALEHI PhD. Immunology Dept. TUMS Importance of Ag-Ab Reactions • Understand the mechanisms of defense • Abs as tools in: – Treatment – Diagnosis • As biomarkers • As tools to measure analytes Nature of Ag/Ab Reactions http://www.med.sc.edu:85/chime2/lyso-abfr.htm • Lock and Key Concept • Non-covalent Bonds – Hydrogen bonds – Electrostatic bonds – Van der Waal forces – Hydrophobic bonds • Multiple Bonds • Reversible Source: Li, Y., Li, H., Smith-Gill, S. J., Mariuzza, R. A., Biochemistry 39, 6296, 2000 Affinity • Strength of the reaction between a single antigenic determinant and a single Ab combining site High Affinity Low Affinity Ab Ab Ag Ag Affinity = ( attractive and repulsive forces Calculation of Affinity Ag + Ab ↔ Ag-Ab Applying the Law of Mass Action: [[gAg-Ab] Keq = [Ag] x [Ab] Avidity • The overall strength of binding between an Ag with many determinants and multivalent Abs 4 6 10 Keq = 10 10 10 Affinity Avidity Avidity SifiitSpecificity • The ability of an individual antibody combining site to react with only one antigenic determinant. • The ability of a population of antibody molecules to react with only one antigen. Cross Reactivity • The ability of an individual Ab combining site to react with more than one antigenic determinant. • The ability of a population of Ab molecules to react with more than one Ag Cross reactions Anti-A Anti-A Anti-A Ab Ab Ab Ag A Ag B Ag C Shared epitope Similar epitope Factors Affecting Measurement of A/AbRAg/Ab Reac tions • Affinity • Avidity Ab excess Ag excess • AAbiAg:Ab ratio •Phyygsical form of Ag Equivalence – Lattice formation Do you need to know what happens in Lab.
    [Show full text]
  • Principles of Immunochemical Techniques Used in Clinical Laboratories
    Review Received 2.11.06 | Revisions Received 3.1.06 | Accepted 3.2.06 Principles of Immunochemical Techniques Used in Clinical Laboratories Marja E. Koivunen, Richard L. Krogsrud (Antibodies Incorporated, Davis, CA) DOI: 10.1309/MV9RM1FDLWAUWQ3F Abstract binding site. The type of antibody and its diseases. Immunoassays can measure low Immunochemistry offers simple, rapid, robust affinity and avidity for the antigen determines levels of disease biomarkers and therapeutic or yet sensitive, and easily automated methods assay sensitivity and specificity. Depending on illicit drugs in patient’s blood, serum, plasma, for routine analyses in clinical laboratories. the assay format, immunoassays can be urine, or saliva. Immunostaining is an example Immunoassays are based on highly specific qualitative or quantitative. They can be used for of an immunochemical technique, which binding between an antigen and an antibody. the detection of antibodies or antigens specific combined with fluorescent labels allows direct An epitope (immunodeterminant region) on the for bacterial, viral, and parasitic diseases as visualization of target cells and cell structures. antigen surface is recognized by the antibody’s well as for the diagnosis of autoimmune Immunochemistry offers simple, rapid, robust yet sensitive, bind to an antigen. The third domain (complement-binding Fc and in most cases, easily automated methods applicable to routine fragment) forms the base of the Y, and is important in immune analyses in clinical laboratories. Immunochemical methods do not system function and regulation. usually require extensive and destructive sample preparation or The region of an antigen that interacts with an antibody is expensive instrumentation. In fact, most methods are based on called an epitope or an immunodeterminant region.
    [Show full text]
  • Igm Autoantibody Testing by Latex Agglutination Nephelometry and Elisa in Patients with Rheumatoid Arthritis
    European Journal of Molecular & Clinical Medicine ISSN 2515-8260 Volume 07, Issue 08, 2020 Comparative Study Of Rheumatoid Factor - Igm Autoantibody Testing By Latex Agglutination Nephelometry And Elisa In Patients With Rheumatoid Arthritis Dr.C. Devi1, Dr.R. Ravichandran2, Dr. Logeswari Selvaraj3, Dr.S. Ramesh4, Dr.T. Aarthipriya5 1,2,3,4,5Senior Assistant professor Department of Microbiology, Government Kilpauk Medical College, Chennai mail id: [email protected] ABSTRACT Objectives: To test Rheumatoid factor (RF) IgM autoantibody in Patients with Rheumatoid Arthritis by various methods like latex agglutination, Nephelometer and ELISA. Comparative analysis of the sensitivity and specificity of the tests performed. Materials and Methods: The study was conducted for a period of six months from June 2018 to November 2018 in a tertiary care hospital in Chennai. 90 patients attending Rheumatology OPD or admitted in the ward with the diagnosis of Rheumatoid arthritis, satisfying the inclusion and exclusion criteria were taken up for the study. Inclusion criteria: Clinically diagnosed Rheumatoid Arthritis patient as per revised ACR 1987 classification criteria. Duration of symptoms (1yr- early (RA) 1 Yr. (Established RA). Exclusion Criteria: Those with systemic connective tissue diseases like SLE, Scleroderma, MCTD, Sjogren syndrome, those with chronic liver diseases, tuberculosis, subacute Bacterial endocarditis, Pregnancy, Lympho reticular malignancies are excluded for the study. Those with onset 16 years of age are also excluded. Under aseptic precautions about 3ml of blood was collected from each Patient. Rheumatoid factor (RF) IgM was tested for each patient by all three methods Latex agglutination, Nephelometry and ELISA. Results: IgM rheumatoid factor (RF) was detected in the sera of 90 patients with Rheumatoid Arthritis.
    [Show full text]
  • Medical & Technical
    MEDICAL & TECHNICAL ARUP Expertise | 2019 JULY 2019 aruplab.com Information in this brochure is current as of July 2019. All content is subject to change. Please contact ARUP Client Services at (800) 522-2787 with any questions or concerns. ARUP supports our clients’ success by providing excellence and consistency in our delivery of services, by sharing knowledge, and by developing progressive laboratory technology. ARUP LABORATORIES ARUP believes in collaborating, sharing knowledge, and contributing to laboratory science in ways that provide the best value for the patient. We operate 24 hours per day, every day of the year, and are a one-stop shop. More than 99 percent of our test menu is performed in-house, providing greater efficiency and standardized test results. ARUP offers one of the broadest test menus in the industry, encompassing more than 3,000 tests and test combinations, including highly specialized and esoteric assays. ARUP’s Laboratory Test Directory contains complete, up-to-date test information, including methodology and reporting times, reference intervals, test notes, and CPT codes. More than 100 medical consultants and experts—nationally and internationally recognized pathologists, subspecialty-qualified clinicians, and board-certified clinical scientists—are available for client consultation. These professionals hold faculty appointments at the University of Utah School of Medicine and make significant contributions in research and development. Many participate in care teams at the Huntsman Cancer Hospital and Primary Children’s Hospital. We are one of the most automated laboratories in the United States, and much of our automation is unique, existing nowhere else in the world. ARUP’s automation would not perform with the intended quality if it were not for the carefully designed and engineered software that integrates separate components into one seamless system.
    [Show full text]
  • Prospective Comparison of Laser Nephelometry with Standard Agglutination Techniques for Detection of Rheumatoid Factor
    J Clin Pathol: first published as 10.1136/jcp.40.2.216 on 1 February 1987. Downloaded from J Clin Pathol 1987;40:216-220 Prospective comparison of laser nephelometry with standard agglutination techniques for detection of rheumatoid factor A G PRENTICE,* P HICKLING,t I C WISEMAN,* C J HOLWILL,* J NORTHWOODt From the Departments oftRheumatology, *Haematology, and IMicrobiology, Derriford Hospital, Plymouth, Devon SUMMARY IgM rheumatoid factor was assayed by three routine methods: latex fixation; haem- agglutination; and end point laser nephelometry in 69 patients with definite or classical rheumatoid arthritis and 58 patients with other non-rheumatoid arthropathies, selected prospectively according to the American Rheumatism Association clinical criteria. The operators of the assays were unaware of the clinical diagnoses. In the group with rheumatoid arthritis 75-4% were positive by latex fixation, 73*9% by haemagglutination, and 55 1% by nephelometry. In the group with non- rheumatoid arthropathies 10-4% were positive by latex fixation, 8-6% by haemagglutination, and 10-4% by nephelometry. Thus the simple and inexpensive latex fixation test was as good as the haemagglutination test, and both were significantly better than nephelometry in the laboratory = confirmation of the clinical diagnosis ofdefinite or classic rheumatoid arthritis (X2 5.40 and 4 56,copyright. and p < 0 025 and < 0 05, respectively). None of these tests was significantly better or worse than the others in producing positive results in the group with non-rheumatoid arthropathies. The diagnosis of rheumatoid arthritis is largely based complexes, which scatter a beam of light in propor- on clinical evidence and depends on the fulfilment of tion to the concentration of the antibody in the test the criteria for definite or classic disease, as described serum.
    [Show full text]
  • Facilities and Other Resources - Overall
    FACILITIES AND OTHER RESOURCES - OVERALL The necessary infrastructure at the University of Utah (prime performance site) and other participating sites (Table 1) are available to support the application, Utah Center for Clinical and Translational Science (Utah CCTS). The assembled team for this innovative center is comprised of experienced principal investigators, mentors and other stakeholders committed to supporting the vision and mission of the Clinical and Translational Science Award (CTSA) consortium. The Principal Investigators, Co-Investigators, and other personnel have the necessary organizational and administrative infrastructure to successfully develop, implement, and evaluate center programs to support the national CTSA consortium. Table 1. Utah CCTS Facilities and Other The Genetic Science Learning Center 4.A Resources Office for Equity and Diversity 4.B Resource Section Center for Law and Biomedical Sciences 4.C Intermountain West 1 The Center for Medical Innovation 4.D The Intermountain West 1.A Vice President’s Clinical & Translational 4.E State of Utah 1.B Scholars Program Salt Lake City 1.C University of Utah Molecular Medicine 4.F University of Utah (U of Utah) and 2 Program University of Utah Health (U Health) Department of Population Health 4.G University Hospital 2.A Sciences Community Clinics 2.B Department of Biomedical Informatics 4.H Huntsman Cancer Institute (Laboratory) 2.C • Biomedical Natural Language • Cancer Biostatistics 2.C.1 Processing 4.H.1 • Pedigree and Population Resource 2.C.2 Entertainment Arts and Engineering 4.I Huntsman Cancer Hospital 2.D Program and GApp Lab University Orthopaedic Center 2.E U Health Core Facilities 5 University Neuropsychiatric Institute 2.F Administration 5.A John A.
    [Show full text]
  • BULLETIN April 24, 2007 SERVING TOOELE COUNTY SINCE 1894 VOL
    FRONT PAGE A1 www.tooeletranscript.com TUESDAY Family fights fires through the generations See B1 TOOELETRANSCRIPT BULLETIN April 24, 2007 SERVING TOOELE COUNTY SINCE 1894 VOL. 113 NO. 96 50¢ Hospital to expand Addition to Mountain West Medical Center will cater to women’s health needs by Mark Watson women can meet to learn the lat- STAFF WRITER est in the world of medicine and A new $4.5 million addition to treatment. Mountain West Medical Center Of the total cost of the new will double the facility’s ability to addition, $1.4 million will be spent care for female patients, accord- on state-of-the-art medical equip- ing to hospital CEO Chuck Davis. ment. Hospital officials announced Davis said market demand was the expansion plans at the behind the decision to expand. Healthy Woman Wellness Fair “The hospital opened on May Thursday night at Tooele High 17, 2002, and during the first year School. The new building will be we had 225 deliveries,” Davis said. located near the main hospital on “During 2006, we had 480 deliv- the northwest side and will have eries. Something needed to be a separate entrance and waiting done.” room, according to Davis. The Davis said the women of the 14,000-square-foot facility should world drive the medical services be completed by the fall of 2008. industry. The hospital is working on archi- “About 70 to 80 percent of med- tectural designs and will seek con- ical decisions are made by women struction bids later in the year. in the community,” he said.
    [Show full text]
  • IMMUNOCHEMICAL TECHNIQUES Antigens Antibodies
    Imunochemical Techniques IMMUNOCHEMICAL TECHNIQUES (by Lenka Fialová, translated by Jan Pláteník a Martin Vejražka) Antigens Antigens are macromolecules of natural or synthetic origin; chemically they consist of various polymers – proteins, polypeptides, polysaccharides or nucleoproteins. Antigens display two essential properties: first, they are able to evoke a specific immune response , either cellular or humoral type; and, second, they specifically interact with products of this immune response , i.e. antibodies or immunocompetent cells. A complete antigen – immunogen – consists of a macromolecule that bears antigenic determinants (epitopes) on its surface (Fig. 1). The antigenic determinant (epitope) is a certain group of atoms on the antigen surface that actually interacts with the binding site on the antibody or lymphocyte receptor for the antigen. Number of epitopes on the antigen surface determines its valency. Low-molecular-weight compound that cannot as such elicit production of antibodies, but is able to react specifically with the products of immune response, is called hapten (incomplete antigen) . antigen epitopes Fig. 1. Antigen and epitopes Antibodies Antibodies are produced by plasma cells that result from differentiation of B lymphocytes following stimulation with antigen. Antibodies are heterogeneous group of animal glycoproteins with electrophoretic mobility β - γ, and are also called immunoglobulins (Ig) . Every immunoglobulin molecule contains at least two light (L) and two heavy (H) chains connected with disulphidic bridges (Fig. 2). One antibody molecule contains only one type of light as well as heavy chain. There are two types of light chains - κ and λ - that determine type of immunoglobulin molecule; while heavy chains exist in 5 isotypes - γ, µ, α, δ, ε; and determine class of immunoglobulins - IgG, IgM, IgA, IgD and IgE .
    [Show full text]